ArticlebioRxiv : the preprint server for biology2026
Evaluating Expert Specialization in Mixture-of-Experts Antibody Language Models.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antibody language models (AbLMs) show an impressive aptitude for learning antibody features, but tend to struggle learning the highly diverse, non-templated regions of antibodies. Existing AbLMs use dense architectures, where all model parameters attend to each amino acid token. We hypothesized that the modular nature of antibodies could benefit from a sparse mixture-of-experts (MoE) architecture, allowing specific parameters (referred to as 'experts') to specialize in distinct antibody features. While MoE architectures are widely adopted and optimized in natural language processing domains, they are less common in biological modeling. To this end, we assess existing MoE routing strategies and find that token-choice routing strategies outperform expert-choice routing, presumably due to their specialization in CDRH3 residues. We further optimized the token-choice router for AbLMs, by minimizing the routing of padding tokens to enable pre-training with varying sequence lengths. Finally, we show that a large-scale baseline antibody language model with a Top-2 MoE architecture (BALM-MoE), trained on a mixture of unpaired and paired antibody sequences, outperforms its dense counterpart with the same number of active parameters.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.